Thomas Gad's most recent trade in Y-Mabs Therapeutics Inc was a trade of 103,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 103,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 03 Jun 2025 | 103,000 | 305,721 (0%) | 0% | 2 | 206,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 5.23 per share. | 07 Mar 2025 | 10,810 | 202,721 (0%) | 0% | 5.2 | 56,536 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 64,000 | 64,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 32,000 | 213,531 (0%) | 0% | 0 | Common Stock | |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 19 Sep 2024 | 22,831 | 181,531 (0%) | 0% | 4.4 | 100,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 22,831 | 143,169 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 13.47 per share. | 13 Sep 2024 | 65,000 | 97,681 (0%) | 0% | 13.5 | 875,550 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 12.97 per share. | 13 Sep 2024 | 30,000 | 67,681 (0%) | 0% | 13.0 | 389,100 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 10 Jun 2024 | 35,000 | 162,681 (0%) | 0% | 12 | 420,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 10 Jun 2024 | 35,000 | 197,681 (0%) | 0% | 12.0 | 421,050 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 21 May 2024 | 25,000 | 240,032 (0%) | 0% | 12 | 300,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 21 May 2024 | 7,351 | 232,681 (0%) | 0% | 13 | 95,563 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 16.44 per share. | 05 Mar 2024 | 3,900 | 158,700 (0%) | 0% | 16.4 | 64,116 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 132,500 | 132,500 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 22,100 | 162,600 (0%) | 0% | 0 | Common Stock | |
| YMabs Therapeutics Inc | Gad Thomas | Director, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 50,000 | 103,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Gad Thomas | Director, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 21 Dec 2023 | 50,000 | 140,500 (0%) | 0% | 2 | 100,000 | Common Stock |
| YMabs Therapeutics Inc | Gad Thomas | Director, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 6.61 per share. | 13 Dec 2023 | 50,000 | 265,032 (0%) | 0% | 6.6 | 330,500 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 6.83 per share. | 13 Dec 2023 | 50,000 | 315,032 (0%) | 0% | 6.8 | 341,500 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 6.58 per share. | 13 Dec 2023 | 50,000 | 365,032 (0%) | 0% | 6.6 | 329,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 243,200 | 243,200 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 40,500 | 90,500 (0%) | 0% | 0 | Common Stock | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 7.01 per share. | 07 Feb 2022 | 125,863 | 629,308 (1%) | 0% | 7.0 | 882,891 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 7.59 per share. | 07 Feb 2022 | 91,031 | 755,171 (1%) | 0% | 7.6 | 691,180 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 6.96 per share. | 07 Feb 2022 | 64,276 | 565,032 (1%) | 0% | 7.0 | 447,117 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 7.70 per share. | 03 Feb 2022 | 101,104 | 846,202 (2%) | 0% | 7.7 | 778,531 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 7.90 per share. | 03 Feb 2022 | 35,060 | 947,306 (2%) | 0% | 7.9 | 277,027 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 01 Feb 2022 | 8,000 | 58,000 (0%) | 0% | 2 | 16,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.15 per share. | 01 Feb 2022 | 8,000 | 50,000 (0%) | 0% | 10.1 | 81,161 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 8,000 | 153,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.96 per share. | 24 Jan 2022 | 55,783 | 982,366 (2%) | 0% | 11.0 | 611,281 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.07 per share. | 24 Jan 2022 | 32,272 | 1,038,149 (2%) | 0% | 10.1 | 325,131 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 11.33 per share. | 20 Jan 2022 | 112,767 | 1,140,739 (2%) | 0% | 11.3 | 1,277,289 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.51 per share. | 20 Jan 2022 | 50,134 | 1,090,605 (2%) | 0% | 10.5 | 526,713 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 11.35 per share. | 20 Jan 2022 | 20,184 | 1,070,421 (2%) | 0% | 11.4 | 229,103 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.89 per share. | 18 Jan 2022 | 69,414 | 1,253,506 (3%) | 0% | 10.9 | 756,092 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 18 Jan 2022 | 8,000 | 58,000 (0%) | 0% | 2 | 16,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 8,000 | 161,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 11.54 per share. | 18 Jan 2022 | 8,000 | 50,000 (0%) | 0% | 11.5 | 92,314 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 11.46 per share. | 18 Jan 2022 | 400 | 1,322,920 (3%) | 0% | 11.5 | 4,584 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 110,000 | 110,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 60,000 | 1,383,320 (3%) | 0% | 0 | Common Stock | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 60,000 | 1,323,320 (3%) | 0% | 0 | Common Stock | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 16.48 per share. | 06 Dec 2021 | 40,000 | 1,397,320 (3%) | 0% | 16.5 | 659,260 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.58 per share. | 06 Dec 2021 | 10,000 | 1,383,320 (3%) | 0% | 17.6 | 175,832 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 16.50 per share. | 06 Dec 2021 | 4,000 | 1,393,320 (3%) | 0% | 16.5 | 65,982 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.16 per share. | 29 Nov 2021 | 22,437 | 1,462,490 (3%) | 0% | 17.2 | 385,026 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.11 per share. | 29 Nov 2021 | 12,800 | 1,449,090 (3%) | 0% | 17.1 | 218,947 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 29 Nov 2021 | 7,770 | 1,441,320 (3%) | 0% | 17.0 | 132,433 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 16.98 per share. | 29 Nov 2021 | 4,000 | 1,437,320 (3%) | 0% | 17.0 | 67,912 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 16.94 per share. | 29 Nov 2021 | 600 | 1,461,890 (3%) | 0% | 16.9 | 10,166 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 23 Nov 2021 | 50,000 | 100,000 (0%) | 0% | 2 | 100,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 50,000 | 169,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.06 per share. | 23 Nov 2021 | 50,000 | 50,000 (0%) | 0% | 17.1 | 852,850 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 19.33 per share. | 16 Nov 2021 | 4,000 | 1,484,927 (3%) | 0% | 19.3 | 77,302 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 24.82 per share. | 29 Oct 2021 | 4,000 | 1,488,927 (3%) | 0% | 24.8 | 99,261 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 27.20 per share. | 15 Oct 2021 | 4,000 | 1,492,927 (3%) | 0% | 27.2 | 108,799 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 28.26 per share. | 30 Sep 2021 | 4,000 | 1,496,927 (3%) | 0% | 28.3 | 113,054 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 33.64 per share. | 15 Sep 2021 | 4,000 | 1,500,927 (3%) | 0% | 33.6 | 134,579 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 33.18 per share. | 02 Sep 2021 | 50,000 | 1,504,927 (3%) | 0% | 33.2 | 1,658,915 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 50,000 | 219,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 02 Sep 2021 | 50,000 | 50,000 (0%) | 0% | 2 | 100,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 29.33 per share. | 13 Aug 2021 | 22,111 | 1,556,706 (3%) | 0% | 29.3 | 648,527 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 29.14 per share. | 13 Aug 2021 | 4,000 | 1,578,817 (3%) | 0% | 29.1 | 116,544 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 13 Aug 2021 | 1,779 | 1,554,927 (3%) | 0% | 29.0 | 51,527 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 31.01 per share. | 13 Aug 2021 | 1,110 | 1,582,817 (3%) | 0% | 31.0 | 34,426 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 33.73 per share. | 03 Aug 2021 | 4,000 | 1,583,927 (3%) | 0% | 33.7 | 134,927 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 32.47 per share. | 20 Jul 2021 | 4,000 | 1,587,927 (3%) | 0% | 32.5 | 129,875 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 31.87 per share. | 07 Jul 2021 | 4,000 | 1,591,927 (4%) | 0% | 31.9 | 127,465 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 33.86 per share. | 30 Jun 2021 | 4,000 | 1,595,927 (4%) | 0% | 33.9 | 135,446 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 36.95 per share. | 28 May 2021 | 4,000 | 1,603,927 (4%) | 0% | 37.0 | 147,813 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 34.07 per share. | 18 May 2021 | 4,000 | 1,607,927 (4%) | 0% | 34.1 | 136,290 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 27.96 per share. | 26 Apr 2021 | 7,000 | 0 (0%) | 0% | 28.0 | 195,731 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 7,000 | 269,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 26 Apr 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 12 Apr 2021 | 7,000 | 0 (0%) | 0% | 26.6 | 186,253 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 7,000 | 276,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 12 Apr 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 26.60 per share. | 12 Apr 2021 | 4,000 | 1,611,927 (4%) | 0% | 26.6 | 106,388 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 30.26 per share. | 01 Apr 2021 | 9,000 | 0 (0%) | 0% | 30.3 | 272,331 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 9,000 | 283,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 01 Apr 2021 | 9,000 | 9,000 (0%) | 0% | 2 | 18,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 30.27 per share. | 01 Apr 2021 | 6,000 | 1,615,927 (4%) | 0% | 30.3 | 181,615 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 15 Mar 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 7,000 | 292,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 15 Mar 2021 | 7,000 | 0 (0%) | 0% | 36.8 | 257,554 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 36.78 per share. | 15 Mar 2021 | 4,000 | 1,621,927 (4%) | 0% | 36.8 | 147,102 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 1,029,927 | 1,625,927 (4%) | 2% | - | Common Stock | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 35.51 per share. | 01 Mar 2021 | 9,000 | 0 (0%) | 0% | 35.5 | 319,611 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 9,000 | 299,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 01 Mar 2021 | 9,000 | 9,000 (0%) | 0% | 2 | 18,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 35.50 per share. | 01 Mar 2021 | 6,000 | 596,000 (1%) | 0% | 35.5 | 213,029 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 47.08 per share. | 16 Feb 2021 | 7,000 | 0 (0%) | 0% | 47.1 | 329,556 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 7,000 | 308,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 16 Feb 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 47.09 per share. | 16 Feb 2021 | 4,000 | 602,000 (1%) | 0% | 47.1 | 188,367 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 41.99 per share. | 01 Feb 2021 | 7,000 | 0 (0%) | 0% | 42.0 | 293,897 | Common Stock |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 7,000 | 315,000 | - | - | Employee Stock Option (right to buy) | |
| YMabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 01 Feb 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |